Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does RIVAROXABAN Cause Upper respiratory tract infection? 101 Reports in FDA Database

Lower Your Cholesterol — The Natural Way

The Oxidized Cholesterol Strategy: a science-backed plan for heart health.

See the Strategy

According to the FDA Adverse Event Reporting System (FAERS), 101 reports of Upper respiratory tract infection have been filed in association with RIVAROXABAN (Rivaroxaban). This represents 0.1% of all adverse event reports for RIVAROXABAN.

101
Reports of Upper respiratory tract infection with RIVAROXABAN
0.1%
of all RIVAROXABAN reports
3
Deaths
77
Hospitalizations

How Dangerous Is Upper respiratory tract infection From RIVAROXABAN?

Of the 101 reports, 3 (3.0%) resulted in death, 77 (76.2%) required hospitalization, and 1 (1.0%) were considered life-threatening.

Is Upper respiratory tract infection Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for RIVAROXABAN. However, 101 reports have been filed with the FAERS database.

What Other Side Effects Does RIVAROXABAN Cause?

Gastrointestinal haemorrhage (20,041) Haemorrhage (6,571) Epistaxis (5,629) Rectal haemorrhage (4,501) Off label use (4,463) Haematuria (4,387) Upper gastrointestinal haemorrhage (4,247) Cerebrovascular accident (4,111) Anaemia (3,907) Acute kidney injury (3,735)

What Other Drugs Cause Upper respiratory tract infection?

ADALIMUMAB (3,306) ETANERCEPT (2,948) TOFACITINIB (1,805) RITUXIMAB (1,713) ABATACEPT (1,623) METHOTREXATE (1,576) TOCILIZUMAB (1,455) APREMILAST (1,437) PREDNISONE (1,354) SECUKINUMAB (1,339)

Which RIVAROXABAN Alternatives Have Lower Upper respiratory tract infection Risk?

RIVAROXABAN vs RIVASTIGMINE RIVAROXABAN vs RIVOTRIL RIVAROXABAN vs RIZATRIPTAN RIVAROXABAN vs ROACTEMRA RIVAROXABAN vs ROCURONIUM

Related Pages

RIVAROXABAN Full Profile All Upper respiratory tract infection Reports All Drugs Causing Upper respiratory tract infection RIVAROXABAN Demographics